Optovue announced the release of AngioAnalytics, an expansion of its OCTA (optical coherence tomography angiography) technology, at the European Society for Cataract and Refractive Surgery (ESCRS) being held in Barcelona, according to a company news release. This new capability will provide clinicians with the ability to quantify the density of blood flow in the retina, the light-sensitive portion of the eye.
“For the first time ever, ophthalmologists will have the ability to detect early, and manage more closely, devastating eye diseases by viewing the density of blood vessels in the retina and measuring the presence or absence of blood flow,” Richard Rosen, MD, FACS, FASRS, CRA, Professor of Ophthalmology and Director or Retina at the New York Eye and Ear Infirmary, said in the news release. “AngioAnalytics expands OCTA technology by introducing quantification so that changes to a patient’s retina can be tracked objectively, potentially even before the patient notices significant vision degradation. This capability allows us to optimize treatment in a way that we have not previously been able to do, and may lead to changes in the clinical management of diabetic retinopathy, age-related macular degeneration, and other diseases that cause progressive vision loss.”
The AngioVue Imaging System embodies OCTA technology, which uses light rays to form detailed three-dimensional images of the retina so physicians can quickly visualize the anatomic structures and any abnormalities present. In less than three seconds, the AngioVue System acquires a single image that complements, and in some cases can replace, the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System is non-invasive and does not require the use of dye injections, which can often obscure the target anatomy, leading to diagnostic uncertainty. The addition of AngioAnalytics to the AngioVue system now provides objective data regarding the areas encompassed by flow and non-flow regions, and creates a visual map of the blood flow in the retina, according to OptoVue.
“Providing clinicians with the ability to quantify blood flow in the retina should allow for earlier and more individualized treatment, without the need or cost of repeated dye injections,” Jay Wei, founder and chief executive officer for Optovue, said in the news release. “We are very pleased with the adoption and utilization of the AngioVue System since its introduction last year, and we expect AngioAnalytics to further its momentum.”
Recent clinical findings from the AngioVue Imaging System will be highlighted in a symposium entitled, “New Technology for Imaging Structure and function from cornea to Retina,” on Saturday, Sept. 5 at 6 pm at the Hotel Fira Congress Barcelona. Additionally demonstrations of the system will be held throughout the congress in the Optovue booth #D06 located in exhibit hall 7.